{"id":"aba-open-label-ol","safety":{"commonSideEffects":[{"rate":"20-30%","effect":"Fatigue"},{"rate":"10-20%","effect":"Diarrhea"},{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Rash"},{"rate":"5-10%","effect":"Pruritus"},{"rate":"5-10%","effect":"Hypothyroidism"},{"rate":"5-10%","effect":"Increased lipase"},{"rate":"5-10%","effect":"Increased amylase"},{"rate":"5-10%","effect":"Hypophosphatemia"},{"rate":"5-10%","effect":"Hypokalemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By blocking the PD-1 receptor, nivolumab prevents cancer cells from evading immune surveillance, leading to an enhanced anti-tumor response. This mechanism is thought to be particularly effective in treating various types of cancer, including melanoma and non-small cell lung cancer. The exact molecular mechanisms underlying nivolumab's efficacy are still being studied.","oneSentence":"Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:47:23.277Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic melanoma"},{"name":"Metastatic non-small cell lung cancer, PD-L1 positive"}]},"trialDetails":[{"nctId":"NCT00095147","phase":"PHASE3","title":"Abatacept and Infliximab in Combination With Methotrexate in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2005-02","conditions":"Rheumatoid Arthritis","enrollment":431}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Orencia"],"phase":"phase_3","status":"active","brandName":"ABA, open-label (OL)","genericName":"ABA, open-label (OL)","companyName":"Bristol-Myers Squibb","companyId":"bristol-myers-squibb","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nivolumab is an immune checkpoint inhibitor that blocks the PD-1 receptor, allowing the immune system to attack cancer cells. Used for Metastatic melanoma, Metastatic non-small cell lung cancer, PD-L1 positive.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}